Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06506643 | Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms | recruiting | Phase 1 / Phase 2 | 36 | Vector Vitale LLCINDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT04083599 | GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 350 | GenmabINDUSTRY | 12 | Aug 4, 2026 | clinicaltrials |
| NCT05554341 |
| Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial |
| active not recruiting |
| Phase 2 |
| 40 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Aug 4, 2026 |
| clinicaltrials |
| NCT06380660 | Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 298 | Acerand Therapeutics (Shanghai) LimitedINDUSTRY | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07744763 | A Phase I/IIa Study of SYS6041 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 260 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 1 | Aug 4, 2026 | clinicaltrials |
| NCT03878095 | Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors | active not recruiting | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Aug 3, 2026 | clinicaltrials |
| NCT04320888 | Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial | active not recruiting | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 3 | Aug 3, 2026 | clinicaltrials |
| NCT04375228 | Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs) | active not recruiting | Phase 2 | 7 | Columbia UniversityOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07397338 | Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors | recruiting | Phase 1 / Phase 2 | 370 | Revolution Medicines, Inc.INDUSTRY | 1 | Aug 3, 2026 | clinicaltrials |
| NCT02535312 | Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin | active not recruiting | Phase 1 / Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT03284385 | Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2 | active not recruiting | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT03872427 | Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study | active not recruiting | Phase 2 | 54 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT05691491 | Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness | recruiting | Phase 1 / Phase 2 | 42 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07336238 | Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies | active not recruiting | Phase 2 | 18 | University of WashingtonOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07738679 | Clinical Trial Evaluating the Efficacy and Safety of TQB3454 Tablets in Participants With Advanced Solid Tumors | not yet recruiting | Phase 2 | 127 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07739966 | A Study of DS-3939a in Participants With Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 400 | Daiichi SankyoINDUSTRY | 0 | Jul 31, 2026 | clinicaltrials |
| NCT04439227 | Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I) | active not recruiting | Phase 2 | 33 | National Cancer Institute (NCI)NIH | 1 | Jul 30, 2026 | clinicaltrials |
| NCT05039632 | Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies | recruiting | Phase 1 / Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT06136897 | Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J) | active not recruiting | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jul 30, 2026 | clinicaltrials |
| NCT06710132 | Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) | active not recruiting | Phase 1 / Phase 2 | 184 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 10 | Jul 30, 2026 | clinicaltrials |
| NCT07669415 | A Study of LM-168 Combined With Other Anti-tumor Treatments in Participants With Advanced Solid Tumors | recruiting | Phase 2 | 108 | LaNova Medicines LimitedINDUSTRY | 1 | Jul 30, 2026 | clinicaltrials |
| NCT02029001 | Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment(MOST plus) | recruiting | Phase 2 | 900 | Centre Leon BerardOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT04198766 | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | recruiting | Phase 1 / Phase 2 | 340 | Inhibrx Biosciences, IncINDUSTRY | 4 | Jul 29, 2026 | clinicaltrials |
| NCT07374419 | Atamparib in Patients With Advanced Solid Tumors(PARP7) | recruiting | Phase 1 / Phase 2 | 178 | Nerviano Medical Sciences (Shanghai) Ltd.INDUSTRY | 1 | Jul 29, 2026 | clinicaltrials |
| NCT06161025 | A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | recruiting | Phase 2 / Phase 3 | 860 | Daiichi SankyoINDUSTRY | 19 | Jul 28, 2026 | clinicaltrials |
| NCT05503797 | A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations | recruiting | Phase 2 | 254 | Fore BiotherapeuticsINDUSTRY | 12 | Jul 27, 2026 | clinicaltrials |
| NCT03155620 | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) | active not recruiting | Phase 2 | 1,377 | National Cancer Institute (NCI)NIH | 4 | Jul 24, 2026 | clinicaltrials |
| NCT03915678 | Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors(AGADIR) | active not recruiting | Phase 2 | 247 | Institut BergoniéOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT04939610 | A Study of 177Lu-FAP-2286 in Advanced Solid Tumors(LuMIERE) | recruiting | Phase 1 / Phase 2 | 222 | Novartis PharmaceuticalsINDUSTRY | 6 | Jul 24, 2026 | clinicaltrials |
| NCT07002203 | Personalized Neoantigen Peptide Vaccines for Solid Tumors | recruiting | Phase 1 / Phase 2 | 10 | Seqker Biosciences, Inc.INDUSTRY | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07460375 | A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 191 | LigaChem Biosciences, Inc.INDUSTRY | 3 | Jul 24, 2026 | clinicaltrials |
| NCT07724756 | Phase II Study of QLC2519 in Pediatric Solid Tumor Participants | recruiting | Phase 2 | 18 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 24, 2026 | clinicaltrials |
| NCT03934372 | Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors | recruiting | Phase 1 / Phase 2 | 70 | Incyte Biosciences International SàrlINDUSTRY | 7 | Jul 23, 2026 | clinicaltrials |
| NCT06234098 | Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors | recruiting | Phase 1 / Phase 2 | 100 | Alyssum TherapeuticsINDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06475300 | A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors | recruiting | Phase 2 | 570 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT07172919 | A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation | recruiting | Phase 2 | 14 | AmgenINDUSTRY | 9 | Jul 23, 2026 | clinicaltrials |
| NCT06721689 | PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors(PEEL-224) | recruiting | Phase 1 / Phase 2 | 59 | Theodore LaetschOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07718581 | HMPL-A830 in Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 147 | HutchmedINDUSTRY | 1 | Jul 22, 2026 | clinicaltrials |
| NCT05098132 | Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers(SYNERGY-101) | recruiting | Phase 1 / Phase 2 | 364 | SynthekineINDUSTRY | 4 | Jul 21, 2026 | clinicaltrials |
| NCT07714395 | Evaluate Preliminary Anti-tumor Activity of Elraglusib in Adult Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 100 | Actuate Therapeutics Inc.INDUSTRY | 0 | Jul 20, 2026 | clinicaltrials |
| NCT02721732 | Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic | active not recruiting | Phase 2 | 157 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT04439318 | Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1) | active not recruiting | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jul 17, 2026 | clinicaltrials |
| NCT04439357 | Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2) | active not recruiting | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 1 | Jul 17, 2026 | clinicaltrials |
| NCT05379946 | Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 92 | InventisBio Co., LtdINDUSTRY | 1 | Jul 17, 2026 | clinicaltrials |
| NCT06385483 | Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A) | active not recruiting | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Jul 17, 2026 | clinicaltrials |
| NCT06390826 | Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V) | active not recruiting | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Jul 17, 2026 | clinicaltrials |
| NCT06390839 | Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C) | active not recruiting | Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07712029 | Phase II Study of Becotatug Vedotin Plus Pucotenlimab for Advanced Refractory Solid Tumors With EGFR-Positive | recruiting | Phase 2 | 32 | Tianjin Medical University Second HospitalOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT05673928 | A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB) | recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Aug 5, 2026source: clinicaltrials